63 related articles for article (PubMed ID: 476698)
1. Quantitation of intracellular metabolites of [35S]-6-mercaptopurine in L5178Y cells grown in time-course incubates.
Breter HJ; Zahn RK
Cancer Res; 1979 Sep; 39(9):3744-8. PubMed ID: 476698
[TBL] [Abstract][Full Text] [Related]
2. On the paradoxically concentration-dependent metabolism of 6-mercaptopurine in WEHI-3b murine leukemia cells.
Liliemark J; Pettersson B; Engberg B; Lafolie P; Masquelier M; Peterson C
Cancer Res; 1990 Jan; 50(1):108-12. PubMed ID: 2293545
[TBL] [Abstract][Full Text] [Related]
3. The quantitative determination of metabolites of 6-mercaptopurine in biological materials. VI. Evidence for posttranscriptional modification of 6-thioguanosine residues in RNA from L5178Y cells treated with 6-mercaptopurine.
Breter HJ
Biochim Biophys Acta; 1985 May; 825(1):39-44. PubMed ID: 4039607
[TBL] [Abstract][Full Text] [Related]
4. The quantitative determination of metabolites of 6-mercaptopurine in biological materials. III. The determination of 14C-labeled 6-thiopurines in L5178Y cell extracts using high-pressure liquid cation-exchange chromatography.
Breter HJ; Maidhof A; Zahn RK
Biochim Biophys Acta; 1978 Apr; 518(2):205-15. PubMed ID: 418811
[TBL] [Abstract][Full Text] [Related]
5. Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Barcelos A; Dubbelman B; De Abreu R; Brouwer C; Bökkerink JP; de Haas V; de Groot-Kruseman H; Jansen G; Kaspers GL; Cloos J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):422-33. PubMed ID: 24940700
[TBL] [Abstract][Full Text] [Related]
6. Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine in rabbits.
Tterlikkis L; Day JL; Brown DA; Schroeder EC
Cancer Res; 1983 Apr; 43(4):1675-9. PubMed ID: 6682007
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of 6-mercaptopurine (6MP) in the monkey. I. Disposition from plasma and cerebrospinal fluid following iv bolus.
Narang PK; Chatterji DC; O'Neill D; Poplack DG
Drug Metab Dispos; 1983; 11(1):5-9. PubMed ID: 6132796
[TBL] [Abstract][Full Text] [Related]
8. Cellular pharmacokinetics of mercaptopurine in human neoplastic cells and cell lines.
Zimm S; Johnson GE; Chabner BA; Poplack DG
Cancer Res; 1985 Sep; 45(9):4156-61. PubMed ID: 2411397
[TBL] [Abstract][Full Text] [Related]
9. In vitro metabolism of 6-mercaptopurine by human liver cytosol.
Rowland K; Lennard L; Lilleyman JS
Xenobiotica; 1999 Jun; 29(6):615-28. PubMed ID: 10426560
[TBL] [Abstract][Full Text] [Related]
10. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts.
Bökkerink JP; Stet EH; De Abreu RA; Damen FJ; Hulscher TW; Bakker MA; van Baal JA
Biochem Pharmacol; 1993 Apr; 45(7):1455-63. PubMed ID: 7682415
[TBL] [Abstract][Full Text] [Related]
11. Gross and cellular analysis of 6-mercaptopurine-induced cleft palate in hamster.
Burdett DN; Shah RM
Am J Anat; 1988 Feb; 181(2):179-94. PubMed ID: 3369359
[TBL] [Abstract][Full Text] [Related]
12. Plasma clearance and tissue distribution of partially thiolated polycytidylic acid and its degradation products in rodents.
Kung MP; Ho YK; Lalka D; Bardos TJ
Cancer Res; 1984 Oct; 44(10):4602-6. PubMed ID: 6467215
[TBL] [Abstract][Full Text] [Related]
13. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells.
Wielinga PR; Reid G; Challa EE; van der Heijden I; van Deemter L; de Haas M; Mol C; Kuil AJ; Groeneveld E; Schuetz JD; Brouwer C; De Abreu RA; Wijnholds J; Beijnen JH; Borst P
Mol Pharmacol; 2002 Dec; 62(6):1321-31. PubMed ID: 12435799
[TBL] [Abstract][Full Text] [Related]
14. Application of HPLC to study the kinetics of a branched bi-enzyme system consisting of hypoxanthine-guanine phosphoribosyltransferase and xanthine oxidase--an important biochemical system to evaluate the efficiency of the anticancer drug 6-mercaptopurine in ALL cell line.
Kalra S; Paul MK; Balaram H; Mukhopadhyay AK
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May; 850(1-2):7-14. PubMed ID: 17081813
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of thiopurine metabolites in patients with inflammatory bowel disease-what is actually measured?
Vikingsson S; Carlsson B; Almer SH; Peterson C
Ther Drug Monit; 2009 Jun; 31(3):345-50. PubMed ID: 19363461
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-Hodgkin lymphoma.
Keuzenkamp-Jansen CW; DeAbreu RA; Bökkerink JP; Lambooy MA; Trijbels JM
J Pediatr Hematol Oncol; 1996 May; 18(2):145-50. PubMed ID: 8846126
[TBL] [Abstract][Full Text] [Related]
17. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia.
Bostrom B; Erdmann G
Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):80-6. PubMed ID: 8447563
[TBL] [Abstract][Full Text] [Related]
18. Determination of 6-mercaptopurine and its metabolites in plasma or serum by high performance liquid chromatography.
Sahnoun Z; Serre-Debeauvais F; Lang J; Faucon G; Gavend M
Biomed Chromatogr; 1990 Jul; 4(4):144-7. PubMed ID: 2207374
[TBL] [Abstract][Full Text] [Related]
19. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
Korelitz BI; Mirsky FJ; Fleisher MR; Warman JI; Wisch N; Gleim GW
Am J Gastroenterol; 1999 Nov; 94(11):3248-53. PubMed ID: 10566724
[TBL] [Abstract][Full Text] [Related]
20. Delayed cytotoxicity of 6-mercaptopurine is compatible with mitotic death caused by DNA damage due to incorporation of 6-thioguanine into DNA as 6-thioguanine nucleotide.
Inamochi H; Higashigawa M; Shimono Y; Nagata T; Cao DC; Mao XY; M'soka T; Hori H; Kawasaki H; Sakurai M
J Exp Clin Cancer Res; 1999 Sep; 18(3):417-24. PubMed ID: 10606189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
